Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;20(10):1536-1540.
doi: 10.1111/jch.13385. Epub 2018 Sep 14.

Vascular compliance in women with polycystic ovary syndrome treated with spironolactone

Ozgul Muneyyirci-Delale  1   2 , Sherilyne Co  3 , Nathaniel Winer  4
Affiliations

Vascular compliance in women with polycystic ovary syndrome treated with spironolactone

Ozgul Muneyyirci-Delale et al. J Clin Hypertens (Greenwich). 2018 Oct.

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age in the United States and has been associated with several diseases including cardiovascular disease, obesity, and glucose intolerance. In this study, systolic blood pressure, diastolic blood pressure, pulse pressure (vascular compliance), large artery elasticity, systemic vascular resistance (SVR), total vascular impedance (TVI), and body mass index (BMI) were measured before and after treatment with spironolactone in 10 women with PCOS. Systolic BP, diastolic BP, and BMI were similar prior to treatment and after treatment. Pulse pressure decreased slightly post-treatment compared to pretreatment but not to significance (P = 0.07). The results show that after treatment with spironolactone, there was a statistically significant increase in large artery elasticity (P = 0.047), while there was a statistically significant decrease in SVR and TVI (P = 0.0005 and P = 0.03). This study indicates that treatment with spironolactone improves large artery elasticity and reduces systemic vascular resistance without any change in small artery elasticity.

Keywords: PCOS; cardiovascular; compliance; spironolactone; vascular.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interests to disclose.

References

    1. Ndefo UA, Eaton A, Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. P T. 2013;38(6):336‐355. - PMC - PubMed
    1. NIH Department of Health and Human Services . Beyond infertility: polycystic ovary syndrome (PCOS). Bethesda, MD: NIH; 2008.
    1. Umland EM, Klootwyk J. Menstruation‐related disorders. In: DiPiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy: a pathophysiologic approach, 10th edn. New York: McGraw‐Hill; 2011:1393.
    1. Kim HJ, Adams JM, Gudmundsson JA, Arason G, Pau CT, Welt CK. Polycystic ovary morphology: age‐based ultrasound criteria. Fertil Steril. 2017;108(3):548‐553. - PMC - PubMed
    1. Diamanti‐Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine. 2006;30(1):19‐26. - PubMed

MeSH terms

Substances